Antibody Developability
Antibody Developability - Related Videos
11:08
Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
0 Views •
Cited by 2 •
2018
A modular approach to the synthesis of N-glycans for attachment to an aluminum oxide-coated glass slide (ACG slide) as a glycan microarray has been developed and its use for the profiling of an HIV broadly neutralizing antibody has been demonstrated.
09:08
Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens
0 Views •
Cited by 11 •
2016
In the current climate of scarce resources, new technologies are emerging that allow researchers to conduct studies cheaper, faster and with more precision. Here we describe the development of a bead-based salivary antibody multiplex immunoassay to measure human exposure to multiple environmental pathogens simultaneously.
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
0 Views •
Cited by 34 •
2014
Indirect immunofluorescent (IIF) assays have traditionally been used for the detection of antinuclear antibodies (ANA) in human serum. The presence of these antibodies can aid in the diagnosis of systemic autoimmune rheumatic diseases (SARD). This protocol demonstrates how to effectively perform the IIF technique to accurately detect these autoantibodies.
FAQs
Sequence analysis provides an initial view of molecular features that may influence antibody performance. Experimental assays then test whether those features correspond to useful behaviors, including specific binding, solubility, thermal stability, or a tendency to aggregate. Comparing sequence-based expectations with measured properties helps distinguish promising candidates from molecules requiring engineering or formulation changes.
Antibody developability screens treat aggregation and viscosity as practical liabilities because they can affect production and handling. Aggregation refers to formation of unwanted molecular assemblies, while viscosity describes resistance to flow. Evaluating both alongside solubility helps reveal whether a candidate can maintain suitable physical behavior under relevant formulation conditions. These measurements support candidate comparison before later development stages.
Stress conditions help expose chemical degradation and loss of thermal stability that may not be apparent in an unstressed sample. Formulation variables can influence these outcomes, so testing under defined conditions connects molecular liabilities with storage behavior. This information allows developers to identify weaknesses early and use the results when selecting candidates or designing formulations.
A practical workflow begins with sequence analysis, followed by experimental assays for binding specificity and key biophysical properties. Candidates are examined for solubility, thermal stability, aggregation tendency, viscosity, and chemical degradation, including evaluations under formulation or stress conditions. The resulting profile supports a comparative decision about engineering, formulation development, or further advancement.
Early screening is most useful when several antibody candidates compete for continued development. Measuring developability properties at this stage can identify molecules with unfavorable solubility, stability, aggregation, viscosity, or degradation profiles before substantial resources are committed. The comparison helps prioritize candidates and directs targeted antibody engineering or formulation work.
In biochemistry, developability links an antibody’s molecular structure and sequence to observable performance. This connection matters because therapeutic usefulness depends not only on binding specificity but also on stability, solubility, manufacturability, and storage behavior. Using biochemical measurements to make these links helps reduce late-stage development risk and supports more efficient selection of antibody medicines.